Grade 3 to 4 neutropenia · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
1 finding from 1 review
Treatment adherence (defined as dose delay) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Quality of life ( · adjuvant therapy for early breast cancer
1 finding from 1 review
Disease-free survival · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
1 finding from 1 review
Treatment adherence (defined as dose reduction) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Quality of life · neoadjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease-free survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (before hospital discharge) or BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in death (before hospital discharge) or BPD(supplemental… compared with continuous positive airway pressure (low certainty).
1 finding from 1 review
BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in BPD (supplemental oxygen/respiratory support at 36 weeks'… compared with nasal intermittent positive pressure ventilation (low certainty).
1 finding from 1 review
Treatment failure within 72 hours of trial entry · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in treatment failure within 72 hours of trial entry compared with nasal intermittent positive pressure ventilation (moderate certainty).
1 finding from 1 review
Mechanical ventilation within 72 hours of trial entry · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in mechanical ventilation within 72 hours of trial entry compared with nasal intermittent positive pressure ventilation (moderate certainty).
1 finding from 1 review
Pneumothorax · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in pneumothorax (during assigned treatment) compared with nasal intermittent positive pressure ventilation (moderate certainty).
1 finding from 1 review
Nasal trauma (during assigned treatment) · preterm infants requiring primary respiratory support
Nasal high flow probably leads to lower nasal trauma (during assigned treatment) compared with nasal intermittent positive pressure ventilation (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in death (before hospital discharge) compared with continuous positive airway pressure (low certainty).
1 finding from 1 review
BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in BPD (supplemental oxygen/respiratory support at 36 weeks'… compared with continuous positive airway pressure (low certainty).
1 finding from 1 review